about
Immunologic aspect of ovarian cancer and p53 as tumor antigen.The cancer stem cell: evidence for its origin as an injured autoreactive T cellImmunosuppressive networks in the tumour environment and their therapeutic relevanceEffect of B7.1 costimulation on T-cell based immunity against TAP-negative cancer can be facilitated by TAP1 expressionSalmonella pathogenicity island 2-mediated overexpression of chimeric SspH2 proteins for simultaneous induction of antigen-specific CD4 and CD8 T cells.Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors.Improved cytotoxic T-lymphocyte immune responses to a tumor antigen by vaccines co-expressing the SLAM-associated adaptor EAT-2.The HOXB4 homeoprotein promotes the ex vivo enrichment of functional human embryonic stem cell-derived NK cellsImmunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus AnkaraT cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets.Human leukocyte differentiation antigens as therapeutic targets: the CD molecules and CD antibodies.Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.Cancer immunotherapy: the past, the present and the future.Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli.Regulators of apoptosis: suitable targets for immune therapy of cancer.Development of inCVAX, In situ Cancer Vaccine, and Its Immune Response in Mice with Hepatocellular Cancer.Spontaneous tumor rejection by cbl-b-deficient CD8+ T cellsImmunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process.Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.4-1BB regulates NKG2D costimulation in human cord blood CD8+ T cellsImmune-based Therapy Clinical Trials in Hepatocellular Carcinoma'1-8 interferon inducible gene family': putative colon carcinoma-associated antigens.Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis.Melanoma immunotherapy: historical precedents, recent successes and future prospects.Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.Chitosan nanoparticles as a potential nonviral gene delivery for HPV-16 E7 into mammalian cells.Antitumor activity of human γδ T cells transducted with CD8 and with T-cell receptors of tumor-specific cytotoxic T lymphocytes.Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness.Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy.Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice.Anti-tumor immunity via the superoxide-eosinophil axis induced by a lipophilic component of Mycobacterium lipomannan.Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes.Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer.
P2860
Q24814703-07936EEF-F522-4127-B297-E0082801BC2CQ25256839-ECE01025-B199-47DB-9301-0762856F7F8CQ29619244-3AB771AA-1595-4B9F-B8A0-4B591930A7A3Q33486534-8FF365C7-21E0-4C5D-90FF-6837A526B575Q33559019-CB1BAAFA-6975-464E-A88D-DACBFF75DBF3Q33613430-0D991553-9C71-428D-B3D2-365219E3AC98Q34025520-F4700009-AAC3-41C6-914D-E0DB4AEE10AFQ34071227-EEC8F69B-A7ED-4577-B0ED-1F9FCAB9343EQ34080911-5ED9C151-5DA2-499F-91D3-BC9033704BC1Q34326201-C1682072-ABBD-42F3-8000-C3A090F5E81DQ34343169-4E246972-3CA4-4FD8-A7ED-76A0CA37E141Q34343664-10D3DFB5-D314-459C-8476-B679969CD50DQ34451956-E95E5166-2C3B-4870-B9EC-0DF9137C25B9Q34503830-18B18C5C-F334-43A1-8E1D-309CA882C74EQ34657661-E25BE372-48B4-4B6F-9063-3E0FB6A8B93BQ35083647-94F0FC2C-36C3-4C99-8F24-E4247946E8F3Q35834680-85E1E23B-0A8B-438D-B469-CBC8C79B967EQ36111911-7F4E6039-598D-4854-A1C7-86E3861BDCD8Q36140389-910947CD-FA64-46DD-AF7E-D88D584944FDQ36229277-1DEA4E90-2EB9-46F8-8F7F-2FD667DB69C9Q36370554-47ACC55D-8511-4174-B9AA-C36CCE7456C1Q36376333-7EBE70CD-7904-4B1A-9D41-94FA066BCE43Q36407095-D93055CD-4E31-4BFA-8234-C3530A22A136Q36571270-4D72CB68-9A57-4A7C-91FC-78FF56D02ACCQ36610764-1AEEA0E0-3366-43EB-B78F-D0BFA36453B4Q36696103-CD529876-83E4-4F0C-8510-128CE035F9A5Q38081911-43D12EA3-A68A-401F-9332-776AAA30B5BEQ38305306-FB99F7EA-3C3B-4565-97FD-BA4019517B18Q39014313-85A8E0B8-7BEA-47F8-B2FF-6399E44809DBQ39343577-F3AD0DBF-DEBD-4453-B936-ECA3B9751BA9Q41849280-28D57976-6FE6-460B-9CF1-989F0F504994Q44280889-6C32FF5C-8C67-4B80-A923-B3935C769ACBQ50058499-CAE429AA-05B8-4C8B-9344-94CEFF46F8F0Q50551982-CE9F8554-0DC3-4304-833E-987E327F986FQ52020790-DFA550CD-218A-44E0-881A-E0B5EAA80AA7Q52021863-DC7FC453-314D-4707-A702-B13905DE11B5
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Strategies for immunotherapy of cancer.
@ast
Strategies for immunotherapy of cancer.
@en
type
label
Strategies for immunotherapy of cancer.
@ast
Strategies for immunotherapy of cancer.
@en
prefLabel
Strategies for immunotherapy of cancer.
@ast
Strategies for immunotherapy of cancer.
@en
P2093
P1476
Strategies for immunotherapy of cancer.
@en
P2093
Offringa R
Ossendorp F
van der Burg SH
P304
P356
10.1016/S0065-2776(00)75006-1
P577
2000-01-01T00:00:00Z